FIA
OPRX icon

FNY Investment Advisers’s OptimizeRx OPRX Stock Holding History

FNY Investment Advisers’s Portfolio OPRX Stock Details OPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-11,400
Closed -$118K – 1206
2018
Q2 		$118K Buy
+11,400
New +$117K 0.05% 207

Other funds holding OPRX

WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VCM
Venator Capital Management Toronto, Ontario, Canada $48.7M AUM 87.97% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
TCM
Timpani Capital Management Milwaukee, Wisconsin $209M AUM 62.15% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

FNY Investment Advisers's OPRX Position: Q3 2018 in Review

FNY Investment Advisers sold out of OptimizeRx (OPRX) in Q3 2018, closing a stake of 11,400 shares — an estimated $118K sold.

FNY Investment Advisers first reported a position in OPRX in Q2 2018 and held it in 1 quarter. The position peaked at $118K in Q2 2018. 29 funds tracked by Wall St. Rank hold OPRX as of Q3 2018.

  • FNY Investment Advisers reported no remaining OptimizeRx position as of Q3 2018 after selling out during the quarter.
  • FNY Investment Advisers sold 11,400 OptimizeRx shares in Q3 2018, an estimated $118K.
  • FNY Investment Advisers first reported a position in OptimizeRx in Q2 2018 and held it in 1 quarter.
  • FNY Investment Advisers's OptimizeRx position peaked at $118K in Q2 2018.
  • 29 funds tracked by Wall St. Rank held OptimizeRx as of Q3 2018.

Based on FNY Investment Advisers's 13F filing for Q3 2018, filed 29 Oct 2018.